Karen Seiter

Westchester Medical Center — United States

Medicine · Health Sciences

36h-index4.4kcitations212works0.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(93), Acute Lymphoblastic Leukemia research(38), Chronic Myeloid Leukemia Treatments(36), Chronic Lymphocytic Leukemia Research(31), Cancer therapeutics and mechanisms(25)

Publications212 total

Clinical characteristics and response in olutasidenib-treated Relapsed/Refractory mIDH1 Acute Myeloid Leukemia (AML) patients with stable disease following two treatment cycles
Blood·2025Open Access
AML-619: Olutasidenib as Maintenance Therapy After Treatment Response in Mutated IDH1 (mIDH1) Acute Myeloid Leukemia (AML)
Clinical Lymphoma Myeloma & Leukemia·2025
POSTER: AML-619 Olutasidenib as Maintenance Therapy After Treatment Response in Mutated IDH1 (mIDH1) Acute Myeloid Leukemia (AML)
Clinical Lymphoma Myeloma & Leukemia·2025
UNMASKING CHRONIC EOSINOPHILIC LEUKEMIA: A RARE CAUSE OF EOSINOPHILIC MYOCARDITIS
Journal of the American College of Cardiology·2025Open Access
Time to Response and Overall Survival in Patients with m<i>IDH1</i> Relapsed/Refractory Acute Myeloid Leukemia Treated with Olutasidenib
Blood·2024· 1 citedOpen Access
Healthcare Utilization and Costs Among Patients with Acute Myeloid Leukemia Receiving Oral Azacitidine Maintenance Therapy Versus No Maintenance: A US Claims Database Study
Advances in Therapy·2024· 1 citedOpen Access
Improving adequacy rates of bone marrow aspirate and core biopsies through training and a bedside X-ray device.
Journal of Clinical Oncology·2024
Outcomes of R-MPV followed by ara-c in primary central nervous system lymphoma: A single-center retrospective analysis.
Journal of Clinical Oncology·2024· 1 cited
EE86 Healthcare Resource Utilization (HCRU) and Associated Costs Among Patients with Acute Myeloid Leukemia (AML) Treated with Oral Azacitidine as Maintenance and Those Eligible but Not Treated Using a US Claims Database
Value in Health·2023· 1 citedOpen Access
Calr+ Myelofibrosis/BCR-ABL Chronic Myeloid Leukemia Overlap Syndrome Treated with Asciminib
Blood·2023· 2 cited
CLAG-Based Chemotherapy in Previously Untreated AML Patients: 12 Year Follow-up
Blood·2023Open Access
Equity and Resource Allocation: The Case for Allogeneic Transplant in Emergency Medicaid Patients
Blood·2023· 1 citedOpen Access
Management of Bone Marrow Transplants in Incarcerated Patients with Plasma Cell Dyscrasias: A Case Series
Blood·2023Open Access
Daratumumab for Refractory Autoimmune Leukopenia: A Case Report
Blood·2023Open Access
Factors Impacting Response to Olutasidenib in Patients with mIDH1 Acute Myeloid Leukemia
Blood·2023· 2 citedOpen Access
Treatment Patterns and Outcomes of Patients with Acute Myeloid Leukemia (AML) from 2013 to 2022: A Connect ® Myeloid Registry Study
Blood·2023· 3 citedOpen Access
ABCL-582 Navigating Methotrexate Shortage in Hematologic Malignancy Patients: A Qualitative Analysis
Clinical Lymphoma Myeloma & Leukemia·2023Open Access
POSTER: ABCL-582 Navigating Methotrexate Shortage in Hematologic Malignancy Patients: A Qualitative Analysis
Clinical Lymphoma Myeloma & Leukemia·2023
AML-547 Prognostic Effect of Co-Mutations on Patients With NPM1+ Acute Myeloid Leukemia (AML) Enrolled in the Connect® Myeloid Registry
Clinical Lymphoma Myeloma & Leukemia·2023
POSTER: AML-547 Prognostic Effect of Co-Mutations on Patients With NPM1+ Acute Myeloid Leukemia (AML) Enrolled in the Connect® Myeloid Registry
Clinical Lymphoma Myeloma & Leukemia·2023
page 1 of 11Next →

Frequent Co-authors

Eric J. Feldman(9), Tauseef Ahmed(9), Nancy E. Kemeny(8), Gary J. Schiller(7), Norbert Vey(6), Frank Traganos(6), Zbigniew Darżynkiewicz(6), Donna Niedzwiecki(5), Sarit Assouline(5), Karen Yee(5), H. Dorota Halicka(5), Elin R. Sigurdson(4), Jörge E. Cortes(4), Wendy Stock(4), Giovanni Martinelli(4), Mark W. Drummond(4), Steven Blotner(4), Margaret Kasner(4), Kevin R. Kelly(4), Gwen Nichols(4)